ArticleMultiple sclerosis journal - experimental, translational and clinical
Ellagic acid favorable effects on fatigue, depression and anxiety in patients with multiple sclerosis and moderate disability: A randomized clinical trial.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of the Combination of Epigallocatechin Gallate and Ellagic Acid Supplemented with Ketone Bodies on Energetic Restoration of Mitochondrial Dysfunction and Metabolic Inefficiencies in Patients with Multiple Sclerosis: A Review.International journal of molecular sciences · 2026Review
- Gut-ocular surface axis in dry eye disease: phenotype-specific mechanisms, evidence, and microbiome-targeted interventions.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the impact of ellagic acid (EA) on fatigue, depression, and anxiety in patients with multiple sclerosis (MS) who have moderate disability. Methods: A triple-blind, placebo-controlled clinical trial was conducted. Fifty-eight MS patients were randomly allocated to receive EA or placebo. Measurements of fatigue, depression, and anxiety were taken at the beginning and end of the study. Data analysis was performed via SPSS. Results: Significant improvements were observed in the EA group across several measures: the State-Trait Anxiety Inventory (STAI), the Quick Inventory of Depressive Symptomatology (QIDS), the Hospital Anxiety and Depression Scale (HADS) for both depression and anxiety subscales, and the Modified Fatigue Impact Scale (MFIS), which includes total, cognition, psychosocial, and physical scores (P < 0.001). At the end of the study, significant differences between the EA and placebo groups were noted. Within the EA group, significant changes from baseline were found in EDSS, STAI (p = 0.003), QIDS (p = 0.041), HADS-D (p = 0.032), HADS-A (p = 0.012), total MFIS (p = 0.004), MFIS-Cognition (p = 0.001), MFIS-Psychosocial (p = 0.049), and MFIS-physical (p = 0.001) scores. In the EA group, significant changes from baseline were observed in EDSS, STAI (p = 0.003), QIDS (p = 0.041), HADS-D (p = 0.032), HADS-A (p = 0.012), total MFIS (p = 0.004), MFIS-Cognition (p = 0.001), MFIS-Psychosocial (p = 0.049), and MFIS-physical (p = 0.001) scores. Conclusions: EA appears to significantly alleviate fatigue, depression, and anxiety in MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.